<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03738566</url>
  </required_header>
  <id_info>
    <org_study_id>18-000246</org_study_id>
    <nct_id>NCT03738566</nct_id>
  </id_info>
  <brief_title>Outcomes of Esophageal Self Dilation for Benign Refractory Esophageal Stricture Management</brief_title>
  <official_title>Outcomes of Esophageal Self Dilation for Benign Refractory Esophageal Stricture Management: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Among patients with refractory benign esophageal stricture (RBES) who were treated
      endoscopically, we hypothesized the following:

        1. Compared to a endoscopy as needed approach, esophageal self -dilation therapy (ESDT)
           decreases the number of endoscopic dilation, prolong dysphagia free interval

        2. Esophageal self -dilation therapy is safe and well tolerated therapy

        3. ESDT significantly lower the health cost in managing refractory esophageal stricture
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Benign esophageal strictures can be challenging condition to treat. The mainstay of treatment
      is endoscopic dilations. However, 30 to 40% of these strictures recur despite rigorous
      dilations. Although a consensus definition does not exist, a stricture is typically termed as
      a refractory benign esophageal stricture (RBES), when there is a failure to maintain luminal
      patency after at least 5 endoscopic dilations.

      Patients with RBES are extremely difficult to manage and the current armamentarium includes
      repeated endoscopic dilations, corticosteroid or mitomycin C injections, incisional therapy,
      and/ or temporary stent placement. These procedures are costly, their efficacy can be
      short-lived, and are associated with great burden both for the patient and clinician.

      Esophageal self -dilation therapy (ESDT) is where the patient learns to pass a polyvinyl
      dilator orally on a routine basis. In past, smaller studies, ESDT appears to be effective for
      RBES, reducing the number of endoscopic dilations from an average of 21.7 to an average of 1.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized into one of 2 arms.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The tolerability of esophageal self dilation compared to observation defined as number of endoscopic interventions</measure>
    <time_frame>6 months</time_frame>
    <description>The number of patients who remained free of endoscopic therapy between the two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Esophagram</measure>
    <time_frame>6 months</time_frame>
    <description>The esophagram is an x-ray test that assesses the diameter of the esophagus. Patients whose esophagus achieves and remains 10-12mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mayo Dysphagia Questionnaire 30 Day (MDQ-30)</measure>
    <time_frame>1 year</time_frame>
    <description>The MDQ-30 provides a series of questions for patients regarding their swallowing difficulties over the past 30 days. A total score of 40 or higher indicates positive for dysphagia, and a total score of 15 or lower is considered negative for dysphagia. Scores between 15 and 40 are considered indeterminate for dysphagia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper endoscopy: Number of endoscopic interventions</measure>
    <time_frame>6 months</time_frame>
    <description>Participants who experience dysphagia more than once per week will return for an upper endoscopy and dilation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Esophageal Stricture</condition>
  <condition>Esophageal Dilation</condition>
  <arm_group>
    <arm_group_label>Endoscopic Dilation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients randomized to the observation group will undergo repeat upper endoscopy with dilation as needed if their dysphagia relapses. A relapse will be considered if a patient developed solid food dysphagia at least once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esophageal Self Dilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be instructed to start Esophageal self dilation twice a day. If dysphagia is adequately controlled, and there was no resistance with passing the dilator, patients will be asked to decrease the frequency of ESDT to daily, weekly, and monthly over an average period of 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Esophageal self dilation</intervention_name>
    <description>Esophageal self dilation therapy (ESDT), where the patient learns to pass a polyvinyl dilator orally on a routine basis teaching will take over 1-3 training sessions by one of two esophageal physicians and a nurse. Patients will be instructed to start Esophageal self dilation twice a day. If dysphagia is adequately controlled, and there was no resistance with passing the dilator, patients will be asked to decrease the frequency of ESDT to daily, weekly, and monthly over an average period of 6 months as directed by the esophageal care team.</description>
    <arm_group_label>Esophageal Self Dilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Upper Endoscopy with Dilation</intervention_name>
    <description>Patients will undergo repeat endoscopy and dilation as needed if their dysphagia relapse which is the current standard of care.</description>
    <arm_group_label>Endoscopic Dilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Refractory benign esophageal stricture defined as an esophageal stricture with
             persistent dysphagia despite undergoing 5 endoscopic dilations within a 1 year period.
             Persistent dysphagia will be considered if patients has solid food dysphagia at least
             once a week

        Exclusion Criteria:

          -  Patient with malignant esophageal stricture

          -  Angulated stricture which prevents safe passage of Maloney dilator in office setting

          -  In ability to achieve an esophageal diameter of 10 mm with endoscopic dilation

          -  Known significant esophageal motor disorder (i.e. achalasia, aperistalsis, functional
             obstruction, jackhammer, distal esophageal spasm)*

          -  The presence of esophageal stent

          -  Inability to learn self-dilation secondary to blindness or cognitive dysfunction

          -  Use of chronic anticoagulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magnus Halland, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra M Geno</last_name>
      <phone>507-538-0367</phone>
      <email>geno.debra@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Crystal J Tholen</last_name>
      <phone>(507) 538-1361</phone>
      <email>tholen.crystal@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <reference>
    <citation>Spechler SJ. American gastroenterological association medical position statement on treatment of patients with dysphagia caused by benign disorders of the distal esophagus. Gastroenterology. 1999 Jul;117(1):229-33.</citation>
    <PMID>10381932</PMID>
  </reference>
  <reference>
    <citation>Mendelson AH, Small AJ, Agarwalla A, Scott FI, Kochman ML. Esophageal anastomotic strictures: outcomes of endoscopic dilation, risk of recurrence and refractory stenosis, and effect of foreign body removal. Clin Gastroenterol Hepatol. 2015 Feb;13(2):263-271.e1. doi: 10.1016/j.cgh.2014.07.010. Epub 2014 Jul 11.</citation>
    <PMID>25019695</PMID>
  </reference>
  <reference>
    <citation>de Wijkerslooth LR, Vleggaar FP, Siersema PD. Endoscopic management of difficult or recurrent esophageal strictures. Am J Gastroenterol. 2011 Dec;106(12):2080-91; quiz 2092. doi: 10.1038/ajg.2011.348. Epub 2011 Oct 18. Review.</citation>
    <PMID>22008891</PMID>
  </reference>
  <reference>
    <citation>Kochman ML, McClave SA, Boyce HW. The refractory and the recurrent esophageal stricture: a definition. Gastrointest Endosc. 2005 Sep;62(3):474-5.</citation>
    <PMID>16111985</PMID>
  </reference>
  <reference>
    <citation>Hordijk ML, Siersema PD, Tilanus HW, Kuipers EJ. Electrocautery therapy for refractory anastomotic strictures of the esophagus. Gastrointest Endosc. 2006 Jan;63(1):157-63.</citation>
    <PMID>16377340</PMID>
  </reference>
  <reference>
    <citation>Ramage JI Jr, Rumalla A, Baron TH, Pochron NL, Zinsmeister AR, Murray JA, Norton ID, Diehl N, Romero Y. A prospective, randomized, double-blind, placebo-controlled trial of endoscopic steroid injection therapy for recalcitrant esophageal peptic strictures. Am J Gastroenterol. 2005 Nov;100(11):2419-25.</citation>
    <PMID>16279894</PMID>
  </reference>
  <reference>
    <citation>Eloubeidi MA, Lopes TL. Novel removable internally fully covered self-expanding metal esophageal stent: feasibility, technique of removal, and tissue response in humans. Am J Gastroenterol. 2009 Jun;104(6):1374-81. doi: 10.1038/ajg.2009.133. Epub 2009 Apr 28.</citation>
    <PMID>19491851</PMID>
  </reference>
  <reference>
    <citation>Repici A, Hassan C, Sharma P, Conio M, Siersema P. Systematic review: the role of self-expanding plastic stents for benign oesophageal strictures. Aliment Pharmacol Ther. 2010 Jun;31(12):1268-75. doi: 10.1111/j.1365-2036.2010.04301.x. Epub 2010 Mar 17. Review.</citation>
    <PMID>20236257</PMID>
  </reference>
  <reference>
    <citation>Repici A, Vleggaar FP, Hassan C, van Boeckel PG, Romeo F, Pagano N, Malesci A, Siersema PD. Efficacy and safety of biodegradable stents for refractory benign esophageal strictures: the BEST (Biodegradable Esophageal Stent) study. Gastrointest Endosc. 2010 Nov;72(5):927-34. doi: 10.1016/j.gie.2010.07.031.</citation>
    <PMID>21034894</PMID>
  </reference>
  <reference>
    <citation>Nijhawan S, Udawat HP, Nagar P. Aggressive bougie dilatation and intralesional steroids is effective in refractory benign esophageal strictures secondary to corrosive ingestion. Dis Esophagus. 2016 Nov;29(8):1027-1031. doi: 10.1111/dote.12438. Epub 2015 Nov 6.</citation>
    <PMID>26542391</PMID>
  </reference>
  <reference>
    <citation>Repici A, Small AJ, Mendelson A, Jovani M, Correale L, Hassan C, Ridola L, Anderloni A, Ferrara EC, Kochman ML. Natural history and management of refractory benign esophageal strictures. Gastrointest Endosc. 2016 Aug;84(2):222-8. doi: 10.1016/j.gie.2016.01.053. Epub 2016 Jan 30.</citation>
    <PMID>26828759</PMID>
  </reference>
  <reference>
    <citation>Dzeletovic I, Fleischer DE, Crowell MD, Pannala R, Harris LA, Ramirez FC, Burdick GE, Rentz LA, Spratley RV Jr, Helling SD, Alexander JA. Self-dilation as a treatment for resistant, benign esophageal strictures. Dig Dis Sci. 2013 Nov;58(11):3218-23. doi: 10.1007/s10620-013-2822-7. Epub 2013 Aug 8.</citation>
    <PMID>23925823</PMID>
  </reference>
  <reference>
    <citation>Zehetner J, DeMeester SR, Ayazi S, Demeester TR. Home self-dilatation for esophageal strictures. Dis Esophagus. 2014 Jan;27(1):1-4. doi: 10.1111/dote.12030. Epub 2013 Feb 6.</citation>
    <PMID>23387392</PMID>
  </reference>
  <reference>
    <citation>Kachaamy T, Lott D, Crujido LR, Rentz L, Fleischer D. Esophageal luminal restoration for a patient with a long lye-induced stricture via tunnel endoscopic therapy during a rendezvous procedure followed by self-dilation (with video). Gastrointest Endosc. 2014 Jul;80(1):192-4. doi: 10.1016/j.gie.2014.02.026.</citation>
    <PMID>24950654</PMID>
  </reference>
  <reference>
    <citation>Dzeletovic I, Fleischer DE. Self-dilation for resistant, benign esophageal strictures. Am J Gastroenterol. 2010 Oct;105(10):2142-3. doi: 10.1038/ajg.2010.212.</citation>
    <PMID>20927061</PMID>
  </reference>
  <reference>
    <citation>Dzeletovic I, Fleischer DE, Crowell MD, Kim HJ, Harris LA, Burdick GE, McLaughlin RR, Spratley RV Jr, Sharma VK. Self dilation as a treatment for resistant benign esophageal strictures: outcome, technique, and quality of life assessment. Dig Dis Sci. 2011 Feb;56(2):435-40. doi: 10.1007/s10620-010-1503-z. Epub 2011 Jan 8.</citation>
    <PMID>21221805</PMID>
  </reference>
  <reference>
    <citation>Lee HJ, Lee JH, Seo JM, Lee SK, Choe YH. A single center experience of self-bougienage on stricture recurrence after surgery for corrosive esophageal strictures in children. Yonsei Med J. 2010 Mar;51(2):202-5. doi: 10.3349/ymj.2010.51.2.202. Epub 2010 Feb 12.</citation>
    <PMID>20191010</PMID>
  </reference>
  <reference>
    <citation>Wong KK, Hendel D. Self-dilation for refractory oesophageal strictures: an Auckland City Hospital study. N Z Med J. 2010 Aug 27;123(1321):49-53.</citation>
    <PMID>20927157</PMID>
  </reference>
  <reference>
    <citation>Bapat RD, Bakhshi GD, Kantharia CV, Shirodkar SS, Iyer AP, Ranka S. Self-bougienage: long-term relief of corrosive esophageal strictures. Indian J Gastroenterol. 2001 Sep-Oct;20(5):180-2.</citation>
    <PMID>11676328</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Magnus Halland</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, College of Medicine, Consultant, Gastroenterology and Hepatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

